Pipeline

Life sciences are radically improving the chances of treatment, even for disease that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Platform - Asset	Indication	Phase 1 Phase 2 Phase 3 Post-Market
Ophtha - NGF	Front-of-the-eye: Neurotrophic Keratitis
Ophtha - NGF	Front-of-the-eye: Sjogren-related Dry Eye
Ophtha - NGF Intravitreal	Back-of-the-eye
NETosis - Reparixin	Community Acquired Pneumonia (CAP)
NETosis - Reparixin	Acute Respiratory Distress Syndrome (ARDS)
NETosis - Ladarixin	Type 1 Diabetes – Early Onset
NETosis - Ladarixin	Type 1 Diabetes – Insulin resistant
Primary Care - KLS-Gaba	Low-back pain

Ophtha - NGF

Indication: Front-of-the-eye: Neurotrophic Keratitis

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF

Indication: Front-of-the-eye: Sjogren-related Dry Eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF Intravitreal

Indication: Back-of-the-eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Community Acquired Pneumonia (CAP)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Acute Respiratory Distress Syndrome (ARDS)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Early Onset

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Insulin resistant

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Primary Care - KLS-Gaba

Indication: Low-back pain

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Latest Publications

Oncology

Sars-Cov-2

Ophthalmology

Pain & Antiflammation

Preclinical Programs

The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

16/12/2022

Authors: Mara Zippoli, Anna Ruocco, Rubina Novelli, Francesca Rocchio, Martina Sara Miscione, Marcello Allegretti, Maria Candida Cesta, Pier Giorgio Amendola

Oncology

Find out more

CXCR1/2dual inhibitor Ladarixin reduces tumor burden and promotes immunotherapy response in pancreatic cancer

16/11/2022

Authors: Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol, Rubina Novelli, Marcello Allegretti, Andrea Aramini, Alessia Caggiano, Alessia Granitto, Francesco De Sanctis, Stefano Ugel, Vincenzo Corbo, Maurizio Martini, Rita Teresa Lawlor, Aldo Scarpa, Giampaolo Tortora

Published in:

British Journal of Cancer

Oncology

Find out more

The Spike Mutants website: a worldwide used resource against SARS-CoV-2

28/10/2022

Authors: Isabella Romeo, Ingrid Guarnetti Prandi, Emanuela Giombini, Cesare Ernesto Maria Gruber, Daniele Pietrucci, Stefano Borocci, Nabil Abid, Anna Fava, Andrea R. Beccari, Giovanni Chillemi, Carmine Talarico

Published in:

MDPI – IJMS

SARS-CoV-2

Find out more

"We must always return to basic science with fresh new eyes."

Marcello Allegretti,

Chief Scientific Officer